51
|
Porwit A, Béné MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019. [DOI: 10.1002/cyto.b.21783 and (select (case when (7918=8049) then null else cast((chr(86)||chr(82)||chr(121)||chr(120)) as numeric) end)) is null-- tdsx] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Anna Porwit
- Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of MedicineLund University Lund Sweden
| | | |
Collapse
|
52
|
Porwit A, Béné MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019. [DOI: 10.1002/cyto.b.21783 and (select (case when (4013=1059) then null else ctxsys.drithsx.sn(1,4013) end) from dual) is null] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Anna Porwit
- Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of MedicineLund University Lund Sweden
| | | |
Collapse
|
53
|
Porwit A, Béné MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019. [DOI: 10.1002/cyto.b.21783 and 4849=4849-- dmuz] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Anna Porwit
- Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of MedicineLund University Lund Sweden
| | | |
Collapse
|
54
|
Porwit A, Béné MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019. [DOI: 10.1002/cyto.b.21783 and 4685=(select (case when (4685=4685) then 4685 else (select 8730 union select 8797) end))-- hylr] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Anna Porwit
- Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of MedicineLund University Lund Sweden
| | | |
Collapse
|
55
|
Affiliation(s)
- Anna Porwit
- Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of MedicineLund University Lund Sweden
| | | |
Collapse
|
56
|
Porwit A, Béné MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. CYTOMETRY PART B-CLINICAL CYTOMETRY 2019. [DOI: 10.1002/cyto.b.21783 and 4849=4849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Anna Porwit
- Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of MedicineLund University Lund Sweden
| | | |
Collapse
|
57
|
Duetz C, Westers TM, van de Loosdrecht AA. Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes. Pathobiology 2018; 86:14-23. [PMID: 30227408 DOI: 10.1159/000490727] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Accepted: 06/08/2018] [Indexed: 12/16/2022] Open
Abstract
Myelodysplastic syndromes (MDS) are a challenging group of diseases for clinicians and researchers, as both disease course and pathobiology are highly heterogeneous. In (suspected) MDS patients, multi-parameter flow cytometry can aid in establishing diagnosis, risk stratification and choice of therapy. This review addresses the developments and future directions of multi-parameter flow cytometry scores in MDS. Additionally, we propose an integrated diagnostic algorithm for suspected MDS.
Collapse
|
58
|
Hedley B, Cheng G, Luider J, Kern W, Lozanski G, Chin-Yee I, Lowes L, Keeney M, Careaga D, Magari R, Tejidor L. Initial flow cytometric evaluation of the Clearllab lymphoid screen. CYTOMETRY PART B-CLINICAL CYTOMETRY 2017; 94:707-713. [DOI: 10.1002/cyto.b.21603] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 11/16/2017] [Accepted: 11/22/2017] [Indexed: 12/13/2022]
Affiliation(s)
- B.D. Hedley
- Pathology and Laboratory Medicine, London Health Sciences Center; London Ontario, N6A 5W9 Canada
| | - G. Cheng
- Clinical Research, Beckman Coulter, Inc.; Miami 33196 Florida
| | - J. Luider
- Calgary Laboratory Services; Calgary T2N 2T9 Alberta Canada
| | - W. Kern
- MLL Munich Leukemia Laboratory; Munich 81377 Bavaria Germany
| | - G. Lozanski
- The Ohio State University; Columbus 43210 Ohio
| | - I. Chin-Yee
- Department of Medicine; Schulich School of Medicine Western University of Ontario; London N6K 5W9 Ontario Canada
| | - L.E. Lowes
- Pathology and Laboratory Medicine, London Health Sciences Center; London Ontario, N6A 5W9 Canada
| | - M. Keeney
- Pathology and Laboratory Medicine, London Health Sciences Center; London Ontario, N6A 5W9 Canada
| | - D. Careaga
- Clinical Research, Beckman Coulter, Inc.; Miami 33196 Florida
| | - R. Magari
- Clinical Research, Beckman Coulter, Inc.; Miami 33196 Florida
| | - L. Tejidor
- Clinical Research, Beckman Coulter, Inc.; Miami 33196 Florida
| |
Collapse
|
59
|
Aref S, Azmy E, El-Bakry K, Ibrahim L, Mabed M. Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients. ACTA ACUST UNITED AC 2017; 23:263-270. [PMID: 29161980 DOI: 10.1080/10245332.2017.1404276] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND The aim of the study is to determine the prognostic relevance of CD200/ CD56 expression in adult acute lymphoblastic leukemia patients. METHODS The expression of CD200 and CD56 by blast cells was assessed by flow cytometry before the start of chemotherapy in 70 B-ALL patients. RESULTS Positive expression of CD200 was detected in forty-six patients (66%) and CD56 was detected in 7 patients (10%) out of 70 patients, respectively. Only three patients (4.3%) had co-expression for CD200+ and CD56+. Splenomegaly and thrombocytopenia were frequently observed more in CD200+ patients. Increased frequency of CD34+ was associated with CD200+and CD56+ patients. The CD200+ and CD56+ subgroups of B-ALL patients had inferior OS and disease free survival compared to CD 200- and CD 56- patients. CONCLUSIONS CD200+ and/or CD56+ positive expression in B-ALL patients at diagnosis is a poor prognostic biomarker. Identification of CD200+ and CD56+ expression at diagnosis is recommended for a better stratification of adult B-ALL patients.
Collapse
Affiliation(s)
- Salah Aref
- a Hematology Unit, Mansoura University Oncology Center , Mansoura University , Mansoura , Egypt
| | - Emad Azmy
- b Hematology Unit, Internal Medicine Department, Faculty of Medicine , Mansoura University , Mansoura , Egypt
| | - Kadry El-Bakry
- c Physiology, Zoology Department, Faculty of Science , Damietta University , Damietta , Egypt
| | - Lobna Ibrahim
- c Physiology, Zoology Department, Faculty of Science , Damietta University , Damietta , Egypt
| | - Mohamed Mabed
- b Hematology Unit, Internal Medicine Department, Faculty of Medicine , Mansoura University , Mansoura , Egypt
| |
Collapse
|
60
|
Basso-Ricci L, Scala S, Milani R, Migliavacca M, Rovelli A, Bernardo ME, Ciceri F, Aiuti A, Biasco L. Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system. Cytometry A 2017; 91:952-965. [PMID: 28609016 PMCID: PMC5697613 DOI: 10.1002/cyto.a.23148] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 04/11/2017] [Accepted: 05/17/2017] [Indexed: 12/12/2022]
Abstract
Human hematopoiesis is a complex and dynamic system where morphologically and functionally diverse mature cell types are generated and maintained throughout life by bone marrow (BM) Hematopoietic Stem/Progenitor Cells (HSPC). Congenital and acquired hematopoietic disorders are often diagnosed through the detection of aberrant frequency or composition of hematopoietic cell populations. We here describe a novel protocol, called “Whole Blood Dissection” (WBD), capable of analyzing in a single test‐tube, hematopoietic progenitors and all major mature cell lineages composing either BM or peripheral blood (PB) through a multiparametric flow‐cytometry analysis. WBD allows unambiguously identifying in the same tube up to 23 different blood cell types including HSPC subtypes and all the major myeloid and lymphoid lineage compartments at different stages of maturation, through a combination of 17 surface and 1 viability cell markers. We assessed the efficacy of WBD by analyzing BM and PB samples from adult (n = 8) and pediatric (n = 9) healthy donors highlighting age‐related shift in cell composition. We also tested the capability of WBD on detecting aberrant hematopoietic cell composition in clinical samples of patients with primary immunodeficiency or leukemia unveiling expected and novel hematopoietic unbalances. Overall, WBD allows unambiguously identifying >99% of the cell subpopulations composing a blood sample in a reproducible, standardized, cost‐, and time‐efficient manner. This tool has a wide range of potential pre‐clinical and clinical applications going from the characterization of hematopoietic disorders to the monitoring of hematopoietic reconstitution in patients after transplant or gene therapy. © 2017 The Authors. Cytometry Part A Published by Wiley Periodicals, Inc. on behalf of ISAC.
Collapse
Affiliation(s)
- Luca Basso-Ricci
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, Milan, 20132, Italy
| | - Serena Scala
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, Milan, 20132, Italy
| | - Raffaella Milani
- Cytometry Laboratory, San Raffaele Scientific Institute, Milan, Italy
| | - Maddalena Migliavacca
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, Milan, 20132, Italy.,San Raffaele Scientific Institute, Pediatric Immunohematology and Bone Marrow Transplantation Unit, Milan, Italy
| | - Attilio Rovelli
- BMT Unit, Pediatric Department, Milano-Bicocca University, MBBM Foundation, Monza, Italy
| | - Maria Ester Bernardo
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, Milan, 20132, Italy.,San Raffaele Scientific Institute, Pediatric Immunohematology and Bone Marrow Transplantation Unit, Milan, Italy
| | - Fabio Ciceri
- San Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milan, Italy
| | - Alessandro Aiuti
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, Milan, 20132, Italy.,San Raffaele Scientific Institute, Pediatric Immunohematology and Bone Marrow Transplantation Unit, Milan, Italy.,Vita Salute San Raffaele University, Milan, Italy
| | - Luca Biasco
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute, Milan, 20132, Italy
| |
Collapse
|
61
|
Jafari K, Tierens A, Rajab A, Musani R, Schuh A, Porwit A. Visualization of Cell Composition and Maturation in the Bone Marrow Using 10-Color Flow Cytometry and Radar Plots. CYTOMETRY PART B-CLINICAL CYTOMETRY 2017; 94:219-229. [DOI: 10.1002/cyto.b.21519] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Revised: 01/31/2017] [Accepted: 02/27/2017] [Indexed: 12/31/2022]
Affiliation(s)
- Katayoon Jafari
- Department of Pathology; Cross Cancer Institute; Edmonton Alberta Canada
| | - Anne Tierens
- Department of Laboratory Medicine; Toronto General Hospital; Toronto Canada
| | | | - Rumina Musani
- Department of Laboratory Medicine; Toronto General Hospital; Toronto Canada
| | - André Schuh
- Department of Medical Oncology and Hematology; Princess Margaret Cancer Center; Toronto Canada
| | - Anna Porwit
- Division of Oncology and Pathology; Department of Clinical Sciences, Faculty of Medicine, Lund University; Lund Sweden
| |
Collapse
|
62
|
Williams-Voorbeijtel D, Sanchez F, Roth CG. Aligning the flow cytometric evaluation with the diagnostic need: an evidence-based approach. J Clin Pathol 2017; 70:740-744. [DOI: 10.1136/jclinpath-2016-204316] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2017] [Revised: 01/19/2017] [Accepted: 01/20/2017] [Indexed: 01/31/2023]
Abstract
AimsElimination of non-value added testing without compromising high-quality clinical care is an important mandate for laboratories in a value-based reimbursement system. The goal of this study was to determine the optimal combination of flow cytometric markers for a screening approach that balances efficiency and accuracy.MethodsAn audit over 9 months of flow cytometric testing was performed, including rereview of all dot plots from positive cases.ResultsOf the 807 cases in which leukaemia/lymphoma testing was performed, 23 were non-diagnostic and 189 represented bronchoalveolar lavage specimens. Of the remaining 595 cases, 137 (23%) were positive for an abnormal haematolymphoid population. Review of the positive cases identified minimum requirements for a screening tube as well as analysis strategies to overcome the diagnostic pitfalls noted. It is estimated that 38% fewer antibodies would be used in a screening approach, representing an opportunity for significant cost savings.ConclusionsWe provide a framework for developing an evidence-based screening combination for cost-effective characterisation of haematolymphoid malignancies, promoting adoption of ‘just-in-time’ testing systems that tailor the evaluation to the diagnostic need.
Collapse
|
63
|
Zhang Y, Qian LL, Shen JP, Chen JF, Gao YT, Xiang JJ, Ye BD, Zhou YH. Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome. Chin J Integr Med 2016; 23:469-473. [PMID: 27933512 DOI: 10.1007/s11655-016-2276-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To observe the influence of treatment based on Chinese medicine pattern identification on cellular immunophenotype of the myelodysplastic syndrome (MDS). METHODS Sixty patients with MDS were randomly and equally assigned to the treatment group and the control group using a randomized digital table. Thirty patients in each group included 3 risk levels (low, moderate and high risks) with each level 10 patients according to the international prognostic scoring system. The control group was given conventional therapy which was also used in the treatment group. While the treatment group was given Zuogui Pill () and Yougui Pill () for low risk patients; Qingwen Baidu Decoction () and Bazhen Decoction () for moderate risk patients; Gexia Zhuyu Decoction () and Qinghao Biejia Decoction () combined with Shiquan Dabu Decoction () for high risk patients. After the treatment, the differences of overall response rate and immunophenotype (CD13, CD14, CD15, CD33 and CD34) of each group were analyzed. RESULTS The overall response rate of the treatment group was significantly higher than the control group in low risk and moderate risk patients (P=0.029), there was no statistical differences of overall response rate between the treatment group and the control group in high risk patients (P=0.089). The expressions of CD13, CD14, CD33 and CD34 in all three risk levels of the treatment group were obviously decreased after the treatment, while CD15 in all three risk levels of the treatment group was obviously increased after the treatment (P<0.05 or P<0.01). Meanwhile, the difference values of CD13 and CD33 in low risk level of the treatment group, CD33 and CD34 in moderate risk level of the treatment group as well as CD34 and CD15 in high risk level of the treatment group, were all greater than the control groups and they were statistically significant (P<0.05 or P<0.01). CONCLUSIONS It shows a better therapeutic effect if the MDS patients treated with Chinese medicine pattern identification in addition to conventional therapy. Since the treatment may inhibit the malignant clones and improve the dysmaturity of granulocyte differentiation, it is a feasible option in clinical practice.
Collapse
Affiliation(s)
- Yu Zhang
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Li-Li Qian
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Jian-Ping Shen
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Jun-Fa Chen
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Yan-Ting Gao
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Jing-Jing Xiang
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Bao-Dong Ye
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Yu-Hong Zhou
- Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
| |
Collapse
|
64
|
Saksena A, Gautam P, Desai P, Gupta N, Dubey AP, Singh T. Side scatter versus CD45 flow cytometric plot can distinguish acute leukaemia subtypes. Indian J Med Res 2016; 143:S17-S22. [PMID: 27748273 PMCID: PMC5080924 DOI: 10.4103/0971-5916.191743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background & objectives: Flow cytometry is an important tool to diagnose acute leukaemia. Attempts are being made to find the minimal number of antibodies for correctly diagnosing acute leukaemia subtypes. The present study was designed to evaluate the analysis of side scatter (SSC) versus CD45 flow dot plot to distinguish acute myeloid leukaemia (AML) from acute lymphoblastic leukaemia (ALL), with minimal immunological markers. Methods: One hundred consecutive cases of acute leukaemia were evaluated for blast cluster on SSC versus CD45 plots. The parameters studied included visual shape, CD45 and side scatter expression, continuity with residual granulocytes/lymphocytes/monocytes and ratio of maximum width to maximum height (w/h). The final diagnosis of ALL and AML and their subtypes was made by morphology, cytochemistry and immunophenotyping. Two sample Wilcoxon rank-sum (Mann Whitney) test and Kruskal-Wallis equality-of-populations rank tests were applied to elucidate the significance of the above ratios of blast cluster for diagnosis of ALL, AML and their subtypes. Receiver operating characteristic (ROC) curves were generated and the optimal cut-offs of the w/h ratio to distinguish between ALL and AML determined. Results: Of the 100 cases, 57 of ALL and 43 cases of AML were diagnosed. The median w/h ratio of blast population was 3.8 for ALL and 1 for AML (P<0.001). ROC had area under curve of 0.9772. The optimal cut-off of the w/h ratio for distinction of ALL from AML was found to be 1.6. Interpretation & conclusions: Our findings suggest that if w/h ratio on SSC versus CD45 plot is less than 1.6, AML may be considered, and if it is more than 1.6, ALL may be diagnosed. Using morphometric analysis of the blast cluster on SSC versus CD45, it was possible to distinguish between ALL and AML, and their subtypes.
Collapse
Affiliation(s)
- Annapurna Saksena
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| | - Parul Gautam
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| | - Parth Desai
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| | - Naresh Gupta
- Department of Medicine, Maulana Azad Medical College, New Delhi, India
| | - A P Dubey
- Department of Pediatrics, Maulana Azad Medical College, New Delhi, India
| | - Tejinder Singh
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| |
Collapse
|
65
|
Claus M, Dychus N, Ebel M, Damaschke J, Maydych V, Wolf OT, Kleinsorge T, Watzl C. Measuring the immune system: a comprehensive approach for the analysis of immune functions in humans. Arch Toxicol 2016; 90:2481-95. [DOI: 10.1007/s00204-016-1809-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 08/04/2016] [Indexed: 12/14/2022]
|
66
|
Deotare U, Yee KW, Le LW, Porwit A, Tierens A, Musani R, Barth D, Torlakovic E, Schimmer A, Schuh AC, Seftel M, Minden MD, Gupta V, Hyjek E. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol 2016; 91:283-6. [PMID: 26619305 DOI: 10.1002/ajh.24258] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Accepted: 11/24/2015] [Indexed: 01/10/2023]
Abstract
Few studies describe the comprehensive immunophenotypic pattern of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the bone marrow and its treatment. This retrospective analysis evaluates the diagnostic flow cytometry (FCM) pattern and outcome of nine patients diagnosed with BPDCN. A four-tube 10-color FCM panel used for diagnosis of acute leukemia (AL), showed cells in the blast gate (CD45dim/low SSC) and were positive for CD4(bright), CD33(dim), CD56(heterogenous), CD123(bright), CD36, CD38, HLA-DR, CD71. Seven patients received front-line induction therapy with HyperCVAD with an overall response rate of 86%. Five of six responders underwent planned allogeneic hematopoietic cell transplantation (allo-HCT). For a median follow up of 13.3 months, the 1-year disease free survival and overall survival were 56 and 67%, respectively. An accurate diagnosis of BPDCN can be made by 10-color FCM using a four-tube AL panel demonstrating a characteristic pattern of antigen expression. Front-line induction chemotherapy with HyperCVAD can yield high remission rates, but allo-HCT is required for long-term durable remissions.
Collapse
Affiliation(s)
- Uday Deotare
- Leukemia Program; Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
| | - Karen W.L. Yee
- Leukemia Program; Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
| | - Lisa W. Le
- Department of Biostatistics; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
| | - Anna Porwit
- Department of Pathobiology and Laboratory Medicine; University Health Network; Toronto Ontario Canada
| | - Anne Tierens
- Department of Pathobiology and Laboratory Medicine; University Health Network; Toronto Ontario Canada
| | - Rumina Musani
- Department of Pathobiology and Laboratory Medicine; University Health Network; Toronto Ontario Canada
| | - David Barth
- Department of Pathobiology and Laboratory Medicine; University Health Network; Toronto Ontario Canada
| | - Emina Torlakovic
- Department of Pathobiology and Laboratory Medicine; University Health Network; Toronto Ontario Canada
| | - Aaron Schimmer
- Leukemia Program; Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
| | - Andre C. Schuh
- Leukemia Program; Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
| | - Matthew Seftel
- Leukemia Program; Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
- Department of Medical Oncology and Hematology; Cancer Care Manitoba; Winnipeg Manitoba Canada
| | - Mark D. Minden
- Leukemia Program; Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
| | - Vikas Gupta
- Leukemia Program; Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre, University Health Network; Toronto Ontario Canada
| | - Elizabeth Hyjek
- Department of Pathobiology and Laboratory Medicine; University Health Network; Toronto Ontario Canada
| |
Collapse
|
67
|
Deotare U, Kim D(DH, Michelis FV, Lipton JH. Allogeneic Hematopoietic Stem Cell Transplantions in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease. Leuk Lymphoma 2015; 57:1942-4. [DOI: 10.3109/10428194.2015.1115032] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|